The potential for antitumor vaccination in acute myelogenous leukemia

Robert J. Arceci

Research output: Contribution to journalArticle

Abstract

While many advances have been made in the treatment of patients with cancer, significant challenges that remain include tumor cell resistance and the toxicity associated with currently used intensive chemotherapeutic regimens. This is particularly true for patients with acute myelogenous leukemia (AML). Most patients with AML usually are able to achieve complete remission, but only a minority obtain long-term survival. In addition, much of the success achieved has been due to escalation of chemotherapeutic dosing and hematopoietic stem cell transplantation. There is thus a great need for improved therapies which would ideally be able to circumvent drug resistance and more specifically target leukemic cells. Advances in immunobiology over the past century have led to new hope for the development of immune mediated vaccine therapies for patients with cancer. This review focuses on the development of vaccine approaches for treatment of AML and some of the potential advantages and problems.

Original languageEnglish (US)
Pages (from-to)80-93
Number of pages14
JournalJournal of Molecular Medicine
Volume76
Issue number2
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Vaccination
Active Immunotherapy
Neoplasms
Hematopoietic Stem Cell Transplantation
Drug Resistance
Therapeutics
Vaccines
Survival

Keywords

  • Acute myelogenous leukemia
  • Cancer vaccines
  • Costimulation
  • Cytokines
  • Immunotherapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The potential for antitumor vaccination in acute myelogenous leukemia. / Arceci, Robert J.

In: Journal of Molecular Medicine, Vol. 76, No. 2, 1998, p. 80-93.

Research output: Contribution to journalArticle

@article{4ae5819bae3e4c429ef859cba8ea848b,
title = "The potential for antitumor vaccination in acute myelogenous leukemia",
abstract = "While many advances have been made in the treatment of patients with cancer, significant challenges that remain include tumor cell resistance and the toxicity associated with currently used intensive chemotherapeutic regimens. This is particularly true for patients with acute myelogenous leukemia (AML). Most patients with AML usually are able to achieve complete remission, but only a minority obtain long-term survival. In addition, much of the success achieved has been due to escalation of chemotherapeutic dosing and hematopoietic stem cell transplantation. There is thus a great need for improved therapies which would ideally be able to circumvent drug resistance and more specifically target leukemic cells. Advances in immunobiology over the past century have led to new hope for the development of immune mediated vaccine therapies for patients with cancer. This review focuses on the development of vaccine approaches for treatment of AML and some of the potential advantages and problems.",
keywords = "Acute myelogenous leukemia, Cancer vaccines, Costimulation, Cytokines, Immunotherapy",
author = "Arceci, {Robert J.}",
year = "1998",
doi = "10.1007/s001090050195",
language = "English (US)",
volume = "76",
pages = "80--93",
journal = "Journal of Molecular Medicine",
issn = "0946-2716",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - The potential for antitumor vaccination in acute myelogenous leukemia

AU - Arceci, Robert J.

PY - 1998

Y1 - 1998

N2 - While many advances have been made in the treatment of patients with cancer, significant challenges that remain include tumor cell resistance and the toxicity associated with currently used intensive chemotherapeutic regimens. This is particularly true for patients with acute myelogenous leukemia (AML). Most patients with AML usually are able to achieve complete remission, but only a minority obtain long-term survival. In addition, much of the success achieved has been due to escalation of chemotherapeutic dosing and hematopoietic stem cell transplantation. There is thus a great need for improved therapies which would ideally be able to circumvent drug resistance and more specifically target leukemic cells. Advances in immunobiology over the past century have led to new hope for the development of immune mediated vaccine therapies for patients with cancer. This review focuses on the development of vaccine approaches for treatment of AML and some of the potential advantages and problems.

AB - While many advances have been made in the treatment of patients with cancer, significant challenges that remain include tumor cell resistance and the toxicity associated with currently used intensive chemotherapeutic regimens. This is particularly true for patients with acute myelogenous leukemia (AML). Most patients with AML usually are able to achieve complete remission, but only a minority obtain long-term survival. In addition, much of the success achieved has been due to escalation of chemotherapeutic dosing and hematopoietic stem cell transplantation. There is thus a great need for improved therapies which would ideally be able to circumvent drug resistance and more specifically target leukemic cells. Advances in immunobiology over the past century have led to new hope for the development of immune mediated vaccine therapies for patients with cancer. This review focuses on the development of vaccine approaches for treatment of AML and some of the potential advantages and problems.

KW - Acute myelogenous leukemia

KW - Cancer vaccines

KW - Costimulation

KW - Cytokines

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0031882130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031882130&partnerID=8YFLogxK

U2 - 10.1007/s001090050195

DO - 10.1007/s001090050195

M3 - Article

C2 - 9500673

AN - SCOPUS:0031882130

VL - 76

SP - 80

EP - 93

JO - Journal of Molecular Medicine

JF - Journal of Molecular Medicine

SN - 0946-2716

IS - 2

ER -